JP7037577B2 - 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 - Google Patents

高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 Download PDF

Info

Publication number
JP7037577B2
JP7037577B2 JP2019550622A JP2019550622A JP7037577B2 JP 7037577 B2 JP7037577 B2 JP 7037577B2 JP 2019550622 A JP2019550622 A JP 2019550622A JP 2019550622 A JP2019550622 A JP 2019550622A JP 7037577 B2 JP7037577 B2 JP 7037577B2
Authority
JP
Japan
Prior art keywords
seq
cells
cell
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019550622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509767A (ja
JP2020509767A5 (enExample
Inventor
アウディ シャピュイ，
トーマス シュミット，
メーガン マカフィー，
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2020509767A publication Critical patent/JP2020509767A/ja
Publication of JP2020509767A5 publication Critical patent/JP2020509767A5/ja
Application granted granted Critical
Publication of JP7037577B2 publication Critical patent/JP7037577B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
JP2019550622A 2017-03-15 2018-03-15 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 Expired - Fee Related JP7037577B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471956P 2017-03-15 2017-03-15
US62/471,956 2017-03-15
PCT/US2018/022759 WO2018170338A2 (en) 2017-03-15 2018-03-15 High affinity mage-a1-specific tcrs and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021039957A Division JP2021090462A (ja) 2017-03-15 2021-03-12 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Publications (3)

Publication Number Publication Date
JP2020509767A JP2020509767A (ja) 2020-04-02
JP2020509767A5 JP2020509767A5 (enExample) 2021-04-22
JP7037577B2 true JP7037577B2 (ja) 2022-03-16

Family

ID=63523985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550622A Expired - Fee Related JP7037577B2 (ja) 2017-03-15 2018-03-15 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
JP2021039957A Pending JP2021090462A (ja) 2017-03-15 2021-03-12 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021039957A Pending JP2021090462A (ja) 2017-03-15 2021-03-12 高親和性ｍａｇｅ−ａ１特異的ｔｃｒ及びその使用

Country Status (13)

Country Link
US (2) US11034748B2 (enExample)
EP (1) EP3595708A4 (enExample)
JP (2) JP7037577B2 (enExample)
KR (1) KR102375033B1 (enExample)
CN (1) CN110582299A (enExample)
AU (1) AU2018234830B2 (enExample)
BR (1) BR112019018863A8 (enExample)
CA (1) CA3055983A1 (enExample)
EA (1) EA201992131A1 (enExample)
IL (1) IL269250A (enExample)
MX (1) MX2019010972A (enExample)
SG (1) SG11201908527SA (enExample)
WO (1) WO2018170338A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
AU2019256536C1 (en) 2018-04-19 2026-01-15 Baylor College Of Medicine Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
MX2021013218A (es) 2019-05-01 2021-12-10 Pact Pharma Inc Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
JP2023513350A (ja) * 2020-02-14 2023-03-30 アダプティミューン・リミテッド がんまたは腫瘍の治療の方法
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN111320703A (zh) * 2020-03-11 2020-06-23 北京双赢科创生物科技有限公司 靶向cd22的嵌合抗原受体及其应用
CN111499763A (zh) * 2020-03-31 2020-08-07 江苏省省级机关医院 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用
EP4149631A1 (en) * 2020-05-13 2023-03-22 Adaptimmune Limited Method of treatment of cancer or tumour
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20250032540A1 (en) 2020-12-14 2025-01-30 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
BR112023021034A2 (pt) * 2021-04-14 2023-12-12 Tscan Therapeutics Inc Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
EP4430402A1 (en) 2021-11-09 2024-09-18 T-Knife GmbH Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN116063458A (zh) * 2022-04-27 2023-05-05 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
CN119317638A (zh) * 2022-06-01 2025-01-14 北京可瑞生物科技有限公司 Mage-a1特异性tcr及其用途
NL2032130B1 (en) * 2022-06-10 2023-12-18 Academisch Ziekenhuis Leiden T cell receptors directed against melanoma-associated antigen and uses thereof
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025146286A1 (en) * 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026125765A1 (en) 2024-12-13 2026-06-18 Immunoscape Pte. Ltd. Combination therapy
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505635A (ja) 2013-01-29 2016-02-25 マックス−デルブリュック−セントラム フュア モレクラーレ メディツィン（エムディーシー） ベルリン−ブッフ Ｍａｇｅ−ａ１を認識する高結合活性結合分子

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
WO2008039969A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
US9803246B2 (en) * 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
CN102295702B (zh) * 2011-08-26 2014-01-29 中国科学院微生物研究所 一种针对t细胞受体可变区特异性单抗的制备方法
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
DK2971045T3 (da) * 2013-03-13 2019-09-16 Health Research Inc Sammensætninger og fremgangsmåder til anvendelse af rekombinante T-celle-receptorer til direkte genkendelse af tumorantigen
WO2015066262A1 (en) 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
JP6476182B2 (ja) * 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
CN106459165B (zh) * 2014-04-01 2021-04-20 拜恩科技细胞&基因治疗有限公司 密封蛋白-6特异性免疫受体和t细胞表位
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
EP3177314B1 (en) * 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
CA2961179A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
US10544392B2 (en) * 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CN106188274A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别rhamm抗原短肽的t细胞受体
AU2016273213B2 (en) * 2015-06-01 2019-03-14 Medigene Immunotherapies Gmbh T cell receptor library
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN105316362B (zh) * 2015-08-19 2020-03-17 暨南大学 一种Dual-RMCE介导的TCR基因置换系统及其方法
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
JP6989138B2 (ja) * 2016-06-17 2022-01-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体及びその使用
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505635A (ja) 2013-01-29 2016-02-25 マックス−デルブリュック−セントラム フュア モレクラーレ メディツィン（エムディーシー） ベルリン−ブッフ Ｍａｇｅ−ａ１を認識する高結合活性結合分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gene Therapy (2005) 12, 140-146

Also Published As

Publication number Publication date
US20210355189A1 (en) 2021-11-18
BR112019018863A8 (pt) 2023-05-02
IL269250A (en) 2019-11-28
MX2019010972A (es) 2019-12-02
US11034748B2 (en) 2021-06-15
JP2020509767A (ja) 2020-04-02
EP3595708A4 (en) 2020-12-16
KR20190129082A (ko) 2019-11-19
BR112019018863A2 (pt) 2020-04-14
CA3055983A1 (en) 2018-09-20
WO2018170338A3 (en) 2019-11-21
AU2018234830B2 (en) 2023-03-02
CN110582299A (zh) 2019-12-17
WO2018170338A2 (en) 2018-09-20
US20200017568A1 (en) 2020-01-16
JP2021090462A (ja) 2021-06-17
KR102375033B1 (ko) 2022-03-15
SG11201908527SA (en) 2019-10-30
AU2018234830A1 (en) 2019-09-26
EA201992131A1 (ru) 2020-02-06
EP3595708A2 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
US11034748B2 (en) High affinity MAGE-A1-specific TCRs and uses thereof
US20240279307A1 (en) Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US12398191B2 (en) BRAF-specific TCRs and uses thereof
JP7611844B2 (ja) 高アビディティｗｔ１ｔ細胞受容体とその使用
JP2025038057A (ja) Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
JP2020535796A (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
TW202317602A (zh) 嵌合多肽
KR20210049119A (ko) Kras 또는 her2 항원을 표적으로 하는 면역요법
JP2020533289A (ja) 養子細胞治療を改善するための方法
JP7737978B2 (ja) Ｗｔ－１に特異的なｔ細胞免疫療法
US12595290B2 (en) T cell receptors specific for mesothelin and their use in immunotherapy
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
WO2022076353A1 (en) Compositions and methods for treating mage-a1-expressing disease
HK40073285A (en) T-cell immunotherapy specific for wt-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210312

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210913

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20211213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220304

R150 Certificate of patent or registration of utility model

Ref document number: 7037577

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees